EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diverse Inhibitors of De Novo Purine Synthesis Promote AICAR ‐Induced AMPK Activation and Glucose Uptake in L6 Myotubes

Klemen Dolinar iD, Katarina Miš iD, Katja Šopar iD, Mateja Šutar iD, Meta Božič iD, Matic Kolar iD, Tim Hropot iD, Pablo M Garcia-Roves iD, Alexander V Chibalin iD, Sergej Pirkmajer iD

BioFactors · 2025

DOI: 10.1002/biof.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Klemen Dolinar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Aminoimidazole Carboxamide, Ribonucleotides, Glucose, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije, Javna Agencija za Raziskovalno Dejavnost RS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate, an immunosuppressant and anticancer drug, promotes glucose uptake and lipid oxidation in skeletal muscle via activation of AMP‐activated protein kinase (AMPK). Methotrexate promotes AMPK activation by inhibiting 5‐aminoimidazole‐4‐carboxamide ribonucleotide (ZMP) formyltransferase/inosine monophosphate (IMP) cyclohydrolase (ATIC), which converts ZMP, an endogenous purine precursor and an active form of the pharmacological AMPK activator AICAR, to IMP during de novo purine synthesis. In addition to methotrexate, inhibition of purine synthesis underpins the therapeutic effects of a number of commonly used immunosuppressive, anticancer, and antimicrobial drugs, raising the question of whether activation of AMPK in skeletal muscle could be a recurrent feature of these drugs. Using L6 myotubes, we found that AICAR‐induced AMPK activation and glucose uptake were enhanced by inhibitors of the conversion of IMP to GMP (mycophenolate mofetil) or of IMP to AMP (alanosine) as well as by indirect inhibitors of human (trimetrexate) and bacterial ATIC (sulfamethoxazole). 6‐Mercaptopurine, which inhibits the conversion of IMP to GMP and AMP, activated AMPK, increased glucose uptake, and suppressed insulin signaling, but did not enhance the effect of AICAR. As determined by measuring oxygen consumption rate, none of these agents suppressed mitochondrial function. Overall, our results indicate that IMP metabolism is a gateway for the modulation of AMPK and its metabolic effects in skeletal muscle cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aminoimidazole CarboxamideRibonucleotidesGlucoseAMP-Activated Protein KinasesMuscle Fibers, SkeletalPurinesAnimalsRatsMethotrexateHumansCell LineEnzyme ActivationMercaptopurineHydroxymethyl and Formyl Transferases

Stichwörter der Autor:innen

AMP‐activated protein kinase (AMPK)folate metabolismglucose uptakeinsulin signalingpurine metabolismskeletal muscle cells

Substanzen

AICA ribonucleotideAminoimidazole CarboxamideRibonucleotidesGlucoseAMP-Activated Protein KinasesPurinesMethotrexateMercaptopurineHydroxymethyl and Formyl Transferases

Autor:innen und Institutionen

  • Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Nutrition, Metabolism and Gene Therapy Group, Diabetes and Metabolism Program, Institut D'investigació Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Department of Molecular Medicine and Surgery, Integrative Physiology, Karolinska Institutet, Stockholm, Sweden.
  • National Research Tomsk State University, Tomsk, Russia.

ORCID-Profile: Klemen Dolinar, Katarina Miš, Katja Šopar, Mateja Šutar, Meta Božič, Matic Kolar, Tim Hropot, Pablo M Garcia-Roves, Alexander V Chibalin, Sergej Pirkmajer

Förderung

  • Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
  • Javna Agencija za Raziskovalno Dejavnost RS

Zitieren

APA

Dolinar, K., Miš, K., Šopar, K., Šutar, M., Božič, M., Kolar, M., Hropot, T., Garcia-Roves, P. M., Chibalin, A. V., & Pirkmajer, S. (2025). Diverse Inhibitors of De Novo Purine Synthesis Promote AICAR ‐Induced AMPK Activation and Glucose Uptake in L6 Myotubes. BioFactors. https://doi.org/10.1002/biof.70037

Vancouver

Dolinar K, Miš K, Šopar K, Šutar M, Božič M, Kolar M, et al. Diverse Inhibitors of De Novo Purine Synthesis Promote AICAR ‐Induced AMPK Activation and Glucose Uptake in L6 Myotubes. BioFactors. 2025. doi:10.1002/biof.70037

BibTeX
@article{Dolinar2025,
  author = {Dolinar, Klemen and Miš, Katarina and Šopar, Katja and Šutar, Mateja and Božič, Meta and Kolar, Matic and Hropot, Tim and Garcia-Roves, Pablo M and Chibalin, Alexander V and Pirkmajer, Sergej},
  title = {Diverse Inhibitors of De Novo Purine Synthesis Promote AICAR ‐Induced AMPK Activation and Glucose Uptake in L6 Myotubes},
  journal = {BioFactors},
  year = {2025},
  doi = {10.1002/biof.70037}
}
Kostenlos starten →